WASHINGTON — Outraged Republican and Democratic lawmakers on Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its life-saving EpiPens and the profits for a company with sales in excess of $11 billion. Defending the company’s business practices, Mylan CEO Heather Bresch told the House Oversight and Government Reform Committee that she wishes the company had “better anticipated the magnitude and acceleration” of the rising prices for some families. “We never intended this,” Bresch said, but maintained that her company doesn’t make much profit from each emergency allergy shot. The list price of EpiPens has grown to $608 for a two-pack, an increase of more than 500 percent since 2007.